MIRA Pharmaceuticals Q3 2023 Earnings Report $1.10 +0.05 (+4.76%) (As of 12/24/2024 05:19 PM ET) Earnings HistoryForecast MIRA Pharmaceuticals EPS ResultsActual EPS-$0.26Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMIRA Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMIRA Pharmaceuticals Announcement DetailsQuarterQ3 2023Date11/13/2023TimeN/AConference Call ResourcesMIRA Earnings History liberals FOOLED by Elon’s shocking surprise (Ad)Elon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. MIRA Pharmaceuticals Earnings HeadlinesQ4 EPS Forecast for MIRA Pharmaceuticals Lowered by AnalystDecember 23 at 1:35 AM | americanbankingnews.comMIRA Pharmaceuticals submits IND to FDA for Ketamir-2December 21, 2024 | markets.businessinsider.com$19 for a FULL YEAR of stock picks?!We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $19. But why? Because there is a very small window of time... as little as 25 days from now... That will change the market forever.December 26, 2024 | Behind the Markets (Ad)MIRA Makes Major StridesDecember 19, 2024 | msn.comMira Pharmaceuticals appoints new board memberNovember 23, 2024 | uk.investing.comMIRA Pharmaceuticals Appoints New Board Member and ChairmanNovember 23, 2024 | markets.businessinsider.comSee More MIRA Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MIRA Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MIRA Pharmaceuticals and other key companies, straight to your email. Email Address About MIRA PharmaceuticalsMIRA Pharmaceuticals (NASDAQ:MIRA) operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.View MIRA Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings Report Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
